Search Results - "Therapeutic approach"
Suggested Topics within your search.
Suggested Topics within your search.
- therapy 27
- pathology 25
- Alzheimer Disease 15
- drug therapy 15
- Neurodegenerative Diseases 12
- Treatment 12
- metabolism 12
- Chemotherapy 11
- Neoplasms 9
- Risk Factors 9
- Diseases 8
- complications 8
- Cancer 7
- Nervous system 7
- physiology 7
- Alzheimer's disease 6
- Drug Discovery 6
- Drug development 6
- Genetic aspects 6
- Medicine 6
- Medicine & Public Health 6
- Pathology 6
- prevention & control 6
- therapeutic use 6
- Degeneration 5
- etiology 5
- genetics 5
- Antineoplastic agents 4
- Cerebrovascular Disorders 4
- Diagnosis 4
-
61
Hepatic encephalopathy in cirrhosis a disorder of glial-neuronal signalling /
Published 2013Table of Contents: “…Contents: Classification of hepatic encephalopathy -- Hepatic encephalopathy in cirrhosis -- Transjugular intrahepatic portosystemic shunt (TIPS) -- Hepatic encephalopathy post-TIPS -- Neuropathology of hepatic encephalopathy in chronic liver failure -- Cirrhosis-related Parkinsonism -- PET studies in cirrhosis -- Neuroinflammation and hepatic encephalopathy in cirrhosis -- Systemic inflammatory response syndrome (SIRS) in cirrhosis -- Translocator protein and hepatic encephalopathy in cirrhosis -- Modulatory site for neurosteroids -- Prevention and treatment of hepatic encephalopathy in cirrhosis -- Emerging new therapeutic approaches.…”
Get full text
Series
Electronic Video -
62
Hepatic encephalopathy in cirrhosis a disorder of glial-neuronal signalling /
Published 2013Table of Contents: “…Contents: Classification of hepatic encephalopathy -- Hepatic encephalopathy in cirrhosis -- Transjugular intrahepatic portosystemic shunt (TIPS) -- Hepatic encephalopathy post-TIPS -- Neuropathology of hepatic encephalopathy in chronic liver failure -- Cirrhosis-related Parkinsonism -- PET studies in cirrhosis -- Neuroinflammation and hepatic encephalopathy in cirrhosis -- Systemic inflammatory response syndrome (SIRS) in cirrhosis -- Translocator protein and hepatic encephalopathy in cirrhosis -- Modulatory site for neurosteroids -- Prevention and treatment of hepatic encephalopathy in cirrhosis -- Emerging new therapeutic approaches.…”
Get full text
Series
Electronic Video -
63
Lysosomal storage diseases
Published 2019Table of Contents: “…Contents: Lysosomes are multifunctional -- Lysosome related organelles -- Complexity & functions of lysosomal proteins -- Lysosomal storage diseases -- Sphingolipid lysosomal storage diseases as an example -- Lysosomal diseases: multimorbidity disorders -- Pathogenic cascade beyond the Lysosomal System -- Specific therapies approved for some diseases -- Molecular mechanisms and therapeutic approaches of LSDs -- Lysosomal enzymes -- ERTs: approved or in advanced clinical trials -- Approved small molecules: SRT & EET -- Multiple gene therapy trials: enzyme deficiencies -- Cellular organelles targeted by LSD therapies -- Lysosomal & neurodegenerative diseases.…”
Get full text
Series
Electronic Video -
64
Mechanism-based therapies for heart failure and cardiac arrhythmias
Published 2007Table of Contents: “…Contents: Introduction to excitation-contraction coupling -- History of the field of EC coupling -- Introduction to the ryanodine receptor/calcium release channel (RyR2) -- Mechanisms that regulate the RyR2 channel during stress -- Defective regulation of RyR2 in heart failure -- Evidence that diastolic sarcoplasmic reticulum (SR) calcium leak causes heart failure and arrhythmias in vivo -- Novel therapeutic approaches to treating heart failure and preventing sudden cardiac death by fixing the leak in RyR2 channels.…”
Get full text
Series (Calcium signaling 1)
Series (Calcium signaling 2)
Electronic Video -
65
Lysosomal storage diseases
Published 2019Table of Contents: “…Contents: Lysosomes are multifunctional -- Lysosome related organelles -- Complexity & functions of lysosomal proteins -- Lysosomal storage diseases -- Sphingolipid lysosomal storage diseases as an example -- Lysosomal diseases: multimorbidity disorders -- Pathogenic cascade beyond the Lysosomal System -- Specific therapies approved for some diseases -- Molecular mechanisms and therapeutic approaches of LSDs -- Lysosomal enzymes -- ERTs: approved or in advanced clinical trials -- Approved small molecules: SRT & EET -- Multiple gene therapy trials: enzyme deficiencies -- Cellular organelles targeted by LSD therapies -- Lysosomal & neurodegenerative diseases.…”
Get full text
Series
Electronic Video -
66
Mechanism-based therapies for heart failure and cardiac arrhythmias
Published 2007Table of Contents: “…Contents: Introduction to excitation-contraction coupling -- History of the field of EC coupling -- Introduction to the ryanodine receptor/calcium release channel (RyR2) -- Mechanisms that regulate the RyR2 channel during stress -- Defective regulation of RyR2 in heart failure -- Evidence that diastolic sarcoplasmic reticulum (SR) calcium leak causes heart failure and arrhythmias in vivo -- Novel therapeutic approaches to treating heart failure and preventing sudden cardiac death by fixing the leak in RyR2 channels.…”
Get full text
Series (Calcium signaling 1)
Series (Calcium signaling 2)
Electronic Video -
67
Mechanism-based therapies for heart failure and cardiac arrhythmias
Published 2007Table of Contents: “…Contents: Introduction to excitation-contraction coupling -- History of the field of EC coupling -- Introduction to the ryanodine receptor/calcium release channel (RyR2) -- Mechanisms that regulate the RyR2 channel during stress -- Defective regulation of RyR2 in heart failure -- Evidence that diastolic sarcoplasmic reticulum (SR) calcium leak causes heart failure and arrhythmias in vivo -- Novel therapeutic approaches to treating heart failure and preventing sudden cardiac death by fixing the leak in RyR2 channels.…”
Get full text
Series (Calcium signaling 1)
Series (Calcium signaling 2)
Electronic Video -
68
Lysosomal storage diseases
Published 2019Table of Contents: “…Contents: Lysosomes are multifunctional -- Lysosome related organelles -- Complexity & functions of lysosomal proteins -- Lysosomal storage diseases -- Sphingolipid lysosomal storage diseases as an example -- Lysosomal diseases: multimorbidity disorders -- Pathogenic cascade beyond the Lysosomal System -- Specific therapies approved for some diseases -- Molecular mechanisms and therapeutic approaches of LSDs -- Lysosomal enzymes -- ERTs: approved or in advanced clinical trials -- Approved small molecules: SRT & EET -- Multiple gene therapy trials: enzyme deficiencies -- Cellular organelles targeted by LSD therapies -- Lysosomal & neurodegenerative diseases.…”
Get full text
Series
Electronic Video -
69
Psychodynamic self psychology in the treatment of anorexia and bulimia /
Published 2020Taylor & Francis
OCLC metadata license agreement
Electronic eBook -
70
Therapeutic delivery of RNAi
Published 2007Table of Contents: “…Contents: RNAi therapeutics development -- RNAi cellular activity -- In vivo siRNA delivery is key -- Clinically viable siRNA deliveries -- Local delivery of siRNA -- Gene silencing in tumors -- Cancer target validation in vivo -- RNAi effects in mouse brain, joints, eyes and lungs -- siRNA therapeutics in primate models -- Challenges to siRNA systemic delivery -- Systemic delivery technology -- Targeted nanoparticle siRNA delivery -- Self assembled nanoparticle -- Integrin av-beta is a validated target -- Dual-targeted therapeutic approach -- Neovasculature targeting siRNA -- Multi-targeted anti-angiogenesis -- Efficient targeted systemic delivery -- Systemic siRNA delivery to eyes -- Systemic siRNA delivery for neuroblastoma treatment -- Tumor neovasculature inhibition -- siRNA/Atelocollagen anti-tumor efficacy -- Transferrin-mediated systemic delivery -- Antibody-mediated tumor targeting -- Targeted anti-HBV activity -- RNAi effect of chol-siRNA -- PEI-mediated siRNA lung targeting -- Clinicallyviable delivery is the key for successful siRNA therapeutics.…”
Get full text
Series
Electronic Video -
71
Therapeutic delivery of RNAi
Published 2007Table of Contents: “…Contents: RNAi therapeutics development -- RNAi cellular activity -- In vivo siRNA delivery is key -- Clinically viable siRNA deliveries -- Local delivery of siRNA -- Gene silencing in tumors -- Cancer target validation in vivo -- RNAi effects in mouse brain, joints, eyes and lungs -- siRNA therapeutics in primate models -- Challenges to siRNA systemic delivery -- Systemic delivery technology -- Targeted nanoparticle siRNA delivery -- Self assembled nanoparticle -- Integrin av-beta is a validated target -- Dual-targeted therapeutic approach -- Neovasculature targeting siRNA -- Multi-targeted anti-angiogenesis -- Efficient targeted systemic delivery -- Systemic siRNA delivery to eyes -- Systemic siRNA delivery for neuroblastoma treatment -- Tumor neovasculature inhibition -- siRNA/Atelocollagen anti-tumor efficacy -- Transferrin-mediated systemic delivery -- Antibody-mediated tumor targeting -- Targeted anti-HBV activity -- RNAi effect of chol-siRNA -- PEI-mediated siRNA lung targeting -- Clinicallyviable delivery is the key for successful siRNA therapeutics.…”
Get full text
Series
Electronic Video -
72
Therapeutic delivery of RNAi
Published 2007Table of Contents: “…Contents: RNAi therapeutics development -- RNAi cellular activity -- In vivo siRNA delivery is key -- Clinically viable siRNA deliveries -- Local delivery of siRNA -- Gene silencing in tumors -- Cancer target validation in vivo -- RNAi effects in mouse brain, joints, eyes and lungs -- siRNA therapeutics in primate models -- Challenges to siRNA systemic delivery -- Systemic delivery technology -- Targeted nanoparticle siRNA delivery -- Self assembled nanoparticle -- Integrin av-beta is a validated target -- Dual-targeted therapeutic approach -- Neovasculature targeting siRNA -- Multi-targeted anti-angiogenesis -- Efficient targeted systemic delivery -- Systemic siRNA delivery to eyes -- Systemic siRNA delivery for neuroblastoma treatment -- Tumor neovasculature inhibition -- siRNA/Atelocollagen anti-tumor efficacy -- Transferrin-mediated systemic delivery -- Antibody-mediated tumor targeting -- Targeted anti-HBV activity -- RNAi effect of chol-siRNA -- PEI-mediated siRNA lung targeting -- Clinicallyviable delivery is the key for successful siRNA therapeutics.…”
Get full text
Series
Electronic Video -
73
Pain and symptom control in palliative care new ways to think about old drugs /
Published 2009Table of Contents: “…-- Cancer pain: a significant problem -- Pain affects patients throughout the disease course -- Causes of pain in cancer patients -- Pain definitions and pathophysiology -- Consequences of inadequately managed pain -- Relating pain with function -- Pain and symptom assessment -- ABCs of pain and symptom assessment and management -- Therapeutic approaches -- Pharmacotherapy -- Commonly prescribed opioids -- Principles of opioid therapy for effective pain management -- NCCN guidelines for adult cancer pain -- Extended- and regular-released opioids -- Methadone -- Opioid adverse effects -- Opioid rotation -- Managing the poorly responsive patient -- Adjuvant analgesics/co-analgesics -- Procedural interventions -- Nonpharmacologic treatment -- Collateral opioid issues -- Cancer fatigue -- Treatment of fatigue -- Cancer anorexia-cachexia -- Progestational agents.…”
Get full text
Series
Electronic Video -
74
Therapy in cancer 2008 quo vadis? /
Published 2009Table of Contents: “…Contents: Why pursuing new therapeutic approaches in cancer is important -- Prevention and screening -- Current cancer therapy: non-surgical -- Most chemotherapy targets DNA -- Chemotherapy effects -- Current state of cancer therapy: efficacy and toxicity -- Molecular pathogenesis of cancer -- Pursuing targeted therapy in cancers -- Targeted biologic therapies -- Evolving targets and agents -- Shift from chemotherapy to targeted agents -- Clinically established molecular targets in malignancies -- Targeted therapy: proteins and small molecules -- Changes brought about by targeting: efficacy and toxicity -- Biomarkers in drug development -- What is currently known: angiogenesis -- The VEGF family and its receptors -- Bevacizumab and Sorafenib -- Does toxicity correlate with response? …”
Get full text
Series
Electronic Video -
75
Pain and symptom control in palliative care new ways to think about old drugs /
Published 2009Table of Contents: “…-- Cancer pain: a significant problem -- Pain affects patients throughout the disease course -- Causes of pain in cancer patients -- Pain definitions and pathophysiology -- Consequences of inadequately managed pain -- Relating pain with function -- Pain and symptom assessment -- ABCs of pain and symptom assessment and management -- Therapeutic approaches -- Pharmacotherapy -- Commonly prescribed opioids -- Principles of opioid therapy for effective pain management -- NCCN guidelines for adult cancer pain -- Extended- and regular-released opioids -- Methadone -- Opioid adverse effects -- Opioid rotation -- Managing the poorly responsive patient -- Adjuvant analgesics/co-analgesics -- Procedural interventions -- Nonpharmacologic treatment -- Collateral opioid issues -- Cancer fatigue -- Treatment of fatigue -- Cancer anorexia-cachexia -- Progestational agents.…”
Get full text
Series
Electronic Video -
76
Therapy in cancer 2008 quo vadis? /
Published 2009Table of Contents: “…Contents: Why pursuing new therapeutic approaches in cancer is important -- Prevention and screening -- Current cancer therapy: non-surgical -- Most chemotherapy targets DNA -- Chemotherapy effects -- Current state of cancer therapy: efficacy and toxicity -- Molecular pathogenesis of cancer -- Pursuing targeted therapy in cancers -- Targeted biologic therapies -- Evolving targets and agents -- Shift from chemotherapy to targeted agents -- Clinically established molecular targets in malignancies -- Targeted therapy: proteins and small molecules -- Changes brought about by targeting: efficacy and toxicity -- Biomarkers in drug development -- What is currently known: angiogenesis -- The VEGF family and its receptors -- Bevacizumab and Sorafenib -- Does toxicity correlate with response? …”
Get full text
Series
Electronic Video -
77
Therapy in cancer 2008 quo vadis? /
Published 2009Table of Contents: “…Contents: Why pursuing new therapeutic approaches in cancer is important -- Prevention and screening -- Current cancer therapy: non-surgical -- Most chemotherapy targets DNA -- Chemotherapy effects -- Current state of cancer therapy: efficacy and toxicity -- Molecular pathogenesis of cancer -- Pursuing targeted therapy in cancers -- Targeted biologic therapies -- Evolving targets and agents -- Shift from chemotherapy to targeted agents -- Clinically established molecular targets in malignancies -- Targeted therapy: proteins and small molecules -- Changes brought about by targeting: efficacy and toxicity -- Biomarkers in drug development -- What is currently known: angiogenesis -- The VEGF family and its receptors -- Bevacizumab and Sorafenib -- Does toxicity correlate with response? …”
Get full text
Series
Electronic Video -
78
Pain and symptom control in palliative care new ways to think about old drugs /
Published 2009Table of Contents: “…-- Cancer pain: a significant problem -- Pain affects patients throughout the disease course -- Causes of pain in cancer patients -- Pain definitions and pathophysiology -- Consequences of inadequately managed pain -- Relating pain with function -- Pain and symptom assessment -- ABCs of pain and symptom assessment and management -- Therapeutic approaches -- Pharmacotherapy -- Commonly prescribed opioids -- Principles of opioid therapy for effective pain management -- NCCN guidelines for adult cancer pain -- Extended- and regular-released opioids -- Methadone -- Opioid adverse effects -- Opioid rotation -- Managing the poorly responsive patient -- Adjuvant analgesics/co-analgesics -- Procedural interventions -- Nonpharmacologic treatment -- Collateral opioid issues -- Cancer fatigue -- Treatment of fatigue -- Cancer anorexia-cachexia -- Progestational agents.…”
Get full text
Series
Electronic Video -
79
-
80
Targets and emerging therapies for schizophrenia
Published 2012Table of Contents: “…Mailman -- PDE inhibitors as a novel therapeutic approach for schizophrenia / Judith A. Siuciak and William J. …”
An electronic book accessible through the World Wide Web; click to view
Electronic eBook